伟德bv国际体育中国官方网站 is indicated for treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of five French-American-British subtypes including refractory anemia(RA), refractory anemia with ringed sideroblasts(RARS), refractory anemia with excess blasts(RAEB), refractory anemia with excess blasts in transformation(RAEB-t), and chronic myelomonocytic leukemia(CMML) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.